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Leber's hereditary optic neuropathy (LHON) is a genetic disease leading to the loss of central vision and optic nerve atrophy. The existence of
occasional cases of LHON patients developing a Multiple Sclerosis (MS)-like illness and the hypothesis that mtDNA variants may be involved in
MS suggest the possibility of some common molecular mechanisms linking the two diseases. We have pursued a comparative proteomics
approach on cerebrospinal fluid (CSF) samples from LHON and MS patients, as well as healthy donors by employing 2-DE gel separations
coupled to MALDI-TOF-MS and nLC-MS/MS investigations. 7 protein spots showed significant differential distribution among the three groups.
Both CSF of LHON or MS patients are characterized by lower level of transthyretin dimer adduct while a specific up regulation of Apo A-IV was
detected in LHON CSF.
© 2007 Elsevier B.V. All rights reserved.Keywords: Multiple sclerosis; Leber hereditary optic neuropathy; CSF; Biomarkers; Proteomics1. Introduction
Leber's hereditary optic neuropathy (LHON), the first
disease to be linked with a maternally inherited mtDNA point
mutation (Wallace et al., 1988), is a genetic form of retinal⁎ Corresponding authors. Federici is to be contacted at Dipartimento di
Medicina di Laboratorio, Policlinico di Tor Vergata, Italy. Tel./fax: +39
0620902261/2260. Urbani, Centro Europeo Ricerca sul Cervello, IRCCS-
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giorgio.federici@uniroma2.it (G. Federici).
0165-5728/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.jneuroim.2007.10.004ganglion cell degeneration leading to loss of central vision and
optic nerve atrophy occurring predominantly in young males
(Riordan-Eva and Harding, 1995). A subset of LHON patients
present extraocular symptoms involving the central nervous
system (CNS) and these cases are referred to as LHON “plus”
(Riordan-Eva and Harding, 1995). Amongst the LHON “plus”
cases a specific phenotype is the association of LHON with a
disorder indistinguishable from Multiple Sclerosis (MS) (Hard-
ing et al., 1992).
Three pathogenic point mutations at nucleotides 11,778,
3460 and 14,484 of mtDNA, affecting, respectively, ND4, ND1
and ND6 subunit genes of complex I of the respiratory chain,
157S. D'Aguanno et al. / Journal of Neuroimmunology 193 (2008) 156–160are most often associated with the disease (over 95% of LHON
cases) (Riordan-Eva and Harding, 1995) even though other rare
pathogenic mutations have been reported associated to both
complex I and III (Carelli et al., 2004).
The occurrence of cases with the LHON “plus” MS-like
variant has been reported with all three LHON pathogenic
mutations (Vanopdenbosch et al., 2000) fostering various studies
on the possible involvement of mtDNA in MS (Vanopdenbosch
et al., 2000).
Additional genetic (nuclear or mitochondrial) and/or envir-
onmental factors are thought to be involved in incomplete
penetrance and phenotypic expression in LHON (Riordan-Eva
and Harding, 1995; Baracca et al., 2005). The complex I
dysfunction in LHON leads to both a bioenergetic defect and a
chronic increase in reactive oxygen species (ROS) production
(Beretta et al., 2004). A neuropathological study by Kovacs and
colleagues (Kovacs et al., 2005) on a case of LHON,
complicated by a devastating widespread CNS demyelination
including vacuolation of white matter, concludes that mtDNA
mutations affect the nervous system on a metabolic basis, but
occasionally may aggravate or initiate autoimmune processes
such as in the Multiple Sclerosis-like disorder. Recently, aFig. 1. 2-DE slab gel of CSF protein from a Healthy Control individual (A), a MS aff
loaded on non linear pH 3–10 IPG strips. The second dimension was performed on a
and 597 protein spots were detected in the three different group respectively and incmicro-arrays investigation on post-mortem motor cortex from
MS patients identified twenty-six nuclear-encoded mitochon-
drial genes and the functional activities of mitochondrial
respiratory chain complexes I and III to be decreased (Dutta
et al., 2006), suggesting a possible mitochondrial dysfunction in
association to axonal degeneration in MS patients. However, the
link between LHON and MS remains enigmatic due to our poor
understanding of the molecular mechanisms leading to
neurodegeneration in both diseases.
New data available from proteome studies may offer not only
an improved understanding of the pathophysiology of MS and
LHON, but also identify valuable biomarkers. We here report a
comparative cerebrospinal fluid (CSF) proteome investigation
of two LHON cases carrying the 11778/ND4 mutation, five MS
patients and five healthy individuals.
2. Materials and methods
The two LHON cases were both during the acute phase
within 1 month from the disease onset. The five MS patients
were classified as relapsing-remitting MS and the lumbar
puncture was performed during the acute phase. More detailsected individual (B) and a LHON affected individual (C). 30 μg of sample were
9–16% acrylamide gradient. After silver staining an average number of 544, 659
luded in the synthetic master gel (D).
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analysis are reported in Supplemental data file. Samples from
individual subjects have been analysed independently in
replicate experiments after separation of the CSF proteins on
2D electrophoresis (2DE) on non-linear 3–10 pH range 1st
dimension and 2nd dimension on gradient SDS-PAGE 9–16%
(Fig. 1, see Supplemental data file for details). An average
digital CSF proteome map have been created from every single
subject. Protein profile differences have been therefore analysed
imposing the presence of such a protein spot within all the
subjects within the same group.
3. Results and discussion
Seven significant differentially expressed spots were identi-
fied after the statistical analysis of protein spots common to
all the individuals of a clinical group. Because of the limited
number of cases analysed we considered as significant only
changes in protein level above three folds.
These spots were isolated by excision from the 2-DE gels
and identified by MALDI-TOF and LC-MS/MS analysis (see
Supplemental data file for details) — (Table 1) from multiple
gels plugs.
Spots 3102, 3204, and 3203 are found only in MS samples.
These spots were identified by Peptide Mass Fingerprinting
(PMF) as albumin fragment, Ig K V1–5, and Ig j C protein
respectively. Spots 3310 and 8217 are more expressed in MS
patients. The former is an albumin fragment whereas the latter is
a Ig λ light chain VLJ region.
Given the content of albumin in CSF the presence of various
HSA fragments have been often observed in 2DE CSF maps.
Finehout et al. (2004) found 102 different protein spots be-
longing to albumin or albumin fragment. Our data highlight in
5 different cases a well defined fragmentation of HSA in MS
affected individuals. These fragments might be generated by
proteases present in lymphocytes (Kam et al., 2000), which
infiltrate in the CNS (Antel and Owens, 1999).
Moreover, in MS cases we found higher level of lambda and
kappa immunoglobulin chains. Intrathecally generated Igs,
specifically IgG, are found in 95% of MS patients (D'Aguanno
et al., 2007) although oligoclonal bands may be produced in
other condition such as CNS infections and paraneoplastic
syndromes (Sindic and Laterre, 1991). The presence of two or
more oligoclonal bands is considered a positive test for MS
diagnosis (D'Aguanno et al., 2007). Goffette et al. (2004) by
using an immunoaffinity mediated capillary blotting technique
reported the frequent occurrence of CSF specific oligoclonal
free kappa bands (92%), and the less frequent appearance of free
lambda bands (69%) in MS. Interestingly, they found that few
samples negative for oligoclonal IgG in the CSF contained
visible amounts of free kappa bands. This observation
suggested that an intrathecal immune reaction could be more
sensitively detected by the presence of such free kappa chain. In
fact, free kappa bands are poorly represented in the CSF of
patients without neurological disorders and rarely detected in
non-MS neurological diseases (Sindic and Laterre, 1991;
Goffette et al., 2004). Even if this finding is not a novelty in
159S. D'Aguanno et al. / Journal of Neuroimmunology 193 (2008) 156–160the study of MS it could validate the other evidences presented
below.
Higher levels of spot 1316, corresponding to the transthyr-
etin (TTR) dimer, were present in control samples compared to
MS and LHON cases. This transport protein, synthesized
primarily in liver, choroid plexus and the retina, is one of the 23
human proteins known to be associated with local or systemic
amyloidosis (Reixach et al., 2004). TTR is a homotetramer that
carries retinol-binding protein loaded with retinol and thyroxine
(T4) in the plasma and CSF involved in amyloidosis. Senile
systemic amyloidosis is a sporadic disorder resulting from the
deposition of wild-type TTR fibrils in cardiac and other tissues.
Familial amyloidotic polyneuropathy and cardiomyopathy are
hereditary autosomal-dominant diseases, in which the deposited
TTR fibrils are derived from one of 80 known amyloidogenic
mutations, and primarily affect the peripheral and autonomic
nervous systems, and heart, respectively. Brain TTR is secreted
into the cerebrospinal fluid, where becomes the major thyroid
hormone-binding protein. During ontogeny, the maximum TTR
synthesis in the choroid plexus precedes that of the growth rate
of the brain and occurs during the period of maximum
neuroblast replication. TTR is a component of the network
determining thyroid hormone (TH) distribution (Fernandez
et al., 2004). It is well established that TH is required for the
normal timing of differentiation and maturation of oligoden-
drocyte precursor cells (OPCs), the most important source of
remyelinating oligodendrocytes in the adult CNS (Fernandez
et al., 2004). OPCs are present in early (fresh) demyelinating
lesions in MS were they fail to differentiate (Fernandez et al.,
2004). It is reported that the administration of TH during the
acute phase of experimental autoimmune encephalomyelitis
(EAE) in Lewis rats and in Dark Agouti (DA) female rats, the
most commonly used experimental models for MS, is able to
channel OPCs and or progenitors into oligodendroglial lineage,
thus leading to a faster morphological reorganization of myelin
sheaths in the white matter (Fernandez et al., 2004). Our
findings of higher levels of TTR dimer (SSP 1316) in control
individuals compared to MS patients seem to support the idea of
a neuroprotective effect played by thyroid hormone.
The specific Apolipoprotein A-IV spot (SSP 506) has a
three-fold relative concentration increase in CSF of LHON
patients. ApoA-IV is a plasma protein that circulates freely in
solution or associates with chylomicrons and high-density
lipoprotein (HDL). Although ApoA-IV is a major circulating
apolipoprotein, its physiological function is not completely
clear. Several functions have been ascribed to this apolipopro-
tein. For example, it has been shown that ApoA-IV promotes
cholesterol efflux from extra-hepatic tissues, is a ligand for
HDL binding to hepatocytes, activates lecithin:cholesterol
acyltransferase, and modulates the activation of lipoprotein
lipase by ApoCII (Qin et al., 1998). These functions can also be
fulfilled by other apolipoproteins, particularly ApoAI. Over-
expression of either human or mouse ApoA-IV in transgenic
mice confers significant protection against diet-induced athero-
sclerosis in cholesterol-fed animals and apoE-deficient mice
(Qin et al., 1998). It has been suggested that ApoA-IV may play
a protective role against atherosclerosis acting as endogenousinhibitor of lipid oxidation (Qin et al., 1998). Moreover ApoA-
IV aggregates in the regenerating sciatic nerve for myelin
biosynthesis (Olmarker et al., 1996) and is up regulated in CSF
patients with lumbar disc herniation (Liu et al., 2006). The
finding of higher levels of ApoA-IV in CSF from LHON pa-
tients is in agreement with their pathologic conditions char-
acterized by degeneration of the optic nerve and possible ROS
oxidative stress leading to lipid oxidation.
4. Conclusion
This pilot proteomics investigation of CSF protein repertoire
from LHON and MS have highlighted protein patterns, which
allow to differentiate the two diseases, supporting the hypoth-
esis of different molecular mechanisms at the basis of the two
disorders. Moreover, our results underline two specific potential
candidate proteins for further clinical validation studies in order
to foster their application as univariate molecular biomarkers,
which may complement the molecular genetic diagnosis.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
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